Gene therapy market seen reaching $41.63 billion by 2035

Market Research Future projects the global gene therapy market will expand from $7.285 billion in 2025 to $41.63 billion by 2035, driven by genetic disease prevalence, faster approvals, and advances in gene editing. The forecast points to strong growth in oncology, rare diseases, and North America, where demand and R&D spending remain high.

Why it matters: - Gene therapy is moving from niche science to a larger treatment category for genetic, chronic, and rare diseases. - The projected jump to $41.63 billion by 2035 suggests more clinical investment, more manufacturing buildout, and broader patient access to one-time therapies. - The market shift also reflects pressure on health systems to address conditions that traditional treatments do not cure.

What happened: - Market Research Future said the global gene therapy market was valued at $6.12 billion in 2024. - The firm projects the market will rise from $7.285 billion in 2025 to $41.63 billion by 2035. - The forecast implies a 19.04% compound annual growth rate from 2025 to 2035. - The report points to rising prevalence of genetic and chronic disorders, advances in vector engineering and gene editing, and regulatory streamlining as the main growth drivers. - The report also identifies North America as the largest regional market in 2024, with over 45.75% of global revenue, or about $2.8 billion. - Europe held about 30% of the market in 2024, equal to roughly $1.84 billion. - Asia-Pacific accounted for about 20% of global share, while the Middle East and Africa held about 5%.

The details: - The report says noncommunicable diseases account for about 41 million deaths each year worldwide, underscoring the medical need behind gene-based treatments. - CRISPR-Cas9, TALENs, and next-generation viral vectors are improving delivery precision, safety profiles, and durability. - Viral vectors made up about 65% of market revenue in 2024. - Non-viral vectors are gaining traction because developers want safer and more scalable delivery methods. - Antigen-based therapies were the largest gene type segment in 2024, with about 28% share. - Cytokine-based therapies are the fastest-growing gene type, driven by immuno-oncology and inflammatory disease work. - Oncological disorders were the largest application segment in 2024, with about 42% share. - Rare diseases are the fastest-growing indication, supported by interest in hemophilia, inherited retinal dystrophies, and muscular dystrophies. - In vivo gene therapy held a 55% share and remained the dominant delivery route. - Ex vivo gene therapy is the fastest-growing delivery method, especially for hematologic and stem-cell uses. - The report says global pharmaceutical and biotechnology companies are expanding activity in the field. - Novartis remains focused on Zolgensma and gene therapy manufacturing in Switzerland. - Gilead Sciences, through Kite Pharma, has expanded cell therapy capabilities and achieved multiple global approvals for Yescarta. - Spark Therapeutics developed Luxturna, described as the first FDA-approved gene therapy for an inherited retinal disease. - Bluebird bio received FDA approval for Lyfgenia in sickle cell disease. - CRISPR Therapeutics and Sangamo Therapeutics are continuing work in gene editing. - A free sample is available at Request a free sample. - The full report is available at Read detailed insights.

Between the lines: - The forecast is not just a revenue call. It reflects a broader shift toward precision medicine and away from symptom management alone. - The strongest near-term opportunities appear to be in oncology and rare disease, where unmet need and payer willingness to support advanced therapies are highest. - Regulatory fast-tracking could matter as much as scientific progress because approval speed directly affects commercialization and patient access. - The report’s emphasis on manufacturing, partnerships, and supply chains suggests the market’s next bottleneck may be scale, not science.

What's next: - The market is expected to keep expanding through 2035 as more therapies move through clinical development and approval pipelines. - Growth may accelerate in regions with stronger regulatory frameworks, larger R&D budgets, and better reimbursement support. - Companies are likely to invest more in personalized therapies, AI-driven development tools, and localized manufacturing. - The report also points to broader use of digital health for post-treatment monitoring and long-term outcome tracking.

The bottom line: - Gene therapy is projected to become a much larger global market over the next decade, but winning companies will likely need both clinical breakthroughs and manufacturing scale to capture it.